<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="abstract" xml:lang="en"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Headache Pain</journal-id><journal-id journal-id-type="iso-abbrev">J Headache Pain</journal-id><journal-title-group><journal-title>The Journal of Headache and Pain</journal-title></journal-title-group><issn pub-type="ppub">1129-2369</issn><issn pub-type="epub">1129-2377</issn><publisher><publisher-name>Springer</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmc">3620336</article-id><article-id pub-id-type="publisher-id">1129-2377-14-S1-P192</article-id><article-id pub-id-type="doi">10.1186/1129-2377-14-S1-P192</article-id><article-categories><subj-group subj-group-type="heading"><subject>Poster Presentation</subject></subj-group></article-categories><title-group><article-title>Frovatriptan vs almotriptan for treatment of menstrual migraine: a double-blind, randomized, cross-over, multicenter Italian study</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes" id="A1"><name><surname>Bartolini</surname><given-names>M</given-names></name><xref ref-type="aff" rid="I1">1</xref></contrib><contrib contrib-type="author" id="A2"><name><surname>Giamberardino</surname><given-names>MA</given-names></name><xref ref-type="aff" rid="I2">2</xref></contrib><contrib contrib-type="author" id="A3"><name><surname>Lisotto</surname><given-names>C</given-names></name><xref ref-type="aff" rid="I3">3</xref></contrib><contrib contrib-type="author" id="A4"><name><surname>Martelletti</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A5"><name><surname>Moscato</surname><given-names>D</given-names></name><xref ref-type="aff" rid="I4">4</xref></contrib><contrib contrib-type="author" id="A6"><name><surname>Panascia</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I5">5</xref></contrib><contrib contrib-type="author" id="A7"><name><surname>Savi</surname><given-names>L</given-names></name><xref ref-type="aff" rid="I6">6</xref></contrib><contrib contrib-type="author" id="A8"><name><surname>Pini</surname><given-names>LA</given-names></name><xref ref-type="aff" rid="I7">7</xref></contrib><contrib contrib-type="author" id="A9"><name><surname>Sances</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I8">8</xref></contrib><contrib contrib-type="author" id="A10"><name><surname>Santoro</surname><given-names>P</given-names></name><xref ref-type="aff" rid="I9">9</xref></contrib><contrib contrib-type="author" id="A11"><name><surname>Zanchin</surname><given-names>G</given-names></name><xref ref-type="aff" rid="I10">10</xref></contrib><contrib contrib-type="author" id="A12"><name><surname>Omboni</surname><given-names>S</given-names></name><xref ref-type="aff" rid="I11">11</xref></contrib><contrib contrib-type="author" id="A13"><name><surname>Ferrari</surname><given-names>MD</given-names></name><xref ref-type="aff" rid="I12">12</xref></contrib><contrib contrib-type="author" id="A14"><name><surname>Fierro</surname><given-names>B</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib><contrib contrib-type="author" id="A15"><name><surname>Brighina</surname><given-names>F</given-names></name><xref ref-type="aff" rid="I13">13</xref></contrib></contrib-group><aff id="I1"><label>1</label>Clinica Neurologica, Ospedali Riuniti, Universit&#x000e0; Politecnica delle Marche, Ancona, Italy</aff><aff id="I2"><label>2</label>Dipartimento di Medicina e Scienze dell&#x02019;Invecchiamento, Universit&#x000e0; "G. D&#x02019;Annunzio", Chieti, Italy</aff><aff id="I3"><label>3</label>Ospedale Civile San Vito al Tagliamento, Pordenone, Italy</aff><aff id="I4"><label>4</label>UOS Cefalea, Ospedale S. Andrea, Universit&#x000e0; La Sapienza, Roma, Italy</aff><aff id="I5"><label>5</label>Centro Cefalee, A.O. Universitaria Vittorio Emanuele, Catania, Italy</aff><aff id="I6"><label>6</label>Department of Neurology, University of Torino, Italy</aff><aff id="I7"><label>7</label>Centro Cefalee, Universit&#x000e0; degli Studi di Modena e Reggio Emilia, Reggio Emilia, Italy</aff><aff id="I8"><label>8</label>Centro Cefalee, IRCCS Neurologico C. Mondino, Pavia, Italy</aff><aff id="I9"><label>9</label>Clinica Neurologica, Ospedale S. Gerardo, Monza, Italy</aff><aff id="I10"><label>10</label>Department of Neurology, University of Padova, Italy</aff><aff id="I11"><label>11</label>Italian Institute of Telemedicine, Varese, Italy</aff><aff id="I12"><label>12</label>Leiden Centre for Translational Neuroscience, Department of Neurology, Leiden University Medical Centre, Netherlands</aff><aff id="I13"><label>13</label>Department of Neurology and Psichiatry, University of Palermo, Palermo, Italy</aff><pub-date pub-type="ppub"><year>2013</year></pub-date><pub-date pub-type="epub"><day>21</day><month>2</month><year>2013</year></pub-date><volume>14</volume><issue>Suppl 1</issue><supplement><named-content content-type="supplement-title">Abstract Book of The European Headache and Migraine Trust International Congress</named-content><named-content content-type="supplement-editor">Peter J Goadsby and Dominique Valade</named-content><named-content content-type="supplement-sponsor">Publication of this supplement was supported by EHMTIC Limited.</named-content></supplement><fpage>P192</fpage><lpage>P192</lpage><permissions><copyright-statement>Copyright &#x000a9;2013 Bartolini et al; licensee Springer.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>Bartolini et al; licensee Springer.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0">http://creativecommons.org/licenses/by/2.0</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:href="http://www.thejournalofheadacheandpain.com/content/14/S1/P192"/><conference><conf-date>20-23 September 2012</conf-date><conf-name>The European Headache and Migraine Trust International Congress</conf-name><conf-loc>London, UK</conf-loc></conference></article-meta></front><body><sec><title>Objective</title><p>To compare the efficacy and safety of frovatriptan and almotriptan in women with menstrually related migraine (IHS Classification of Headache disorders) enrolled in a multicenter, randomized, double blind, cross-over study.</p></sec><sec sec-type="methods"><title>Methods</title><p>Patients received frovatriptan 2.5 mg or almotriptan 12.5 mg in a randomized sequence: after treating 3 episodes of migraine in no more than 3 months with the first treatment, the patient switched to the other treatment.</p></sec><sec sec-type="results"><title>Results</title><p>67 of the 96 female patients of the intention-to-treat population of the main study had regular menstrual cycles and were thus included in this subgroup analysis. 77 migraine attacks classified as related to menses were treated with frovatriptan and 78 with almotriptan. Rate of pain relief at 2- and 4-hrs was 36% and 53% for frovatriptan and 41% and 50% for almotriptan (p=NS between treatments). Rate of pain free at 2- and 4-hrs was 19% and 47% with frovatriptan and 29% and 54% for almotriptan (p=NS). At 24-hrs, 62% of frovatriptan- and 67% of almotriptan-treated patients had pain relief, while 60% vs. 67% were pain free (p=NS). Recurrence at 24-hrs was significantly (p&#x0003c;0.05) lower with frovatriptan (8% vs. 21% almotriptan). This was the case also at 48-hrs (9% vs. 24%, p&#x0003c;0.05).</p></sec><sec sec-type="conclusions"><title>Conclusions</title><p>Frovatriptan was as effective as almotriptan in the immediate treatment of menstrually related migraine attacks. However, it showed a more favorable sustained effect, as shown by a lower rate of migraine recurrence.</p></sec></body><back><ref-list><ref id="B1"><mixed-citation publication-type="other"><name><surname>Bartolini</surname><given-names>M</given-names></name><name><surname>Giamberardino</surname><given-names>MA</given-names></name><name><surname>Lisotto</surname><given-names>C</given-names></name><name><surname>Martelletti</surname><given-names>P</given-names></name><name><surname>Moscato</surname><given-names>D</given-names></name><name><surname>Panascia</surname><given-names>B</given-names></name><name><surname>Savi</surname><given-names>L</given-names></name><name><surname>Pini</surname><given-names>LA</given-names></name><name><surname>Sances</surname><given-names>G</given-names></name><name><surname>Santoro</surname><given-names>P</given-names></name><name><surname>Zanchin</surname><given-names>G</given-names></name><name><surname>Omboni</surname><given-names>S</given-names></name><name><surname>Ferrari</surname><given-names>MD</given-names></name><name><surname>Brighina</surname><given-names>F</given-names></name><name><surname>Fierro</surname><given-names>B</given-names></name><article-title>Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study</article-title><source>J Headache Pain</source><year>2012</year><pub-id pub-id-type="pmid">22592864</pub-id></mixed-citation></ref></ref-list></back></article>